dCas9-KRAB Cell Lines
Cancelled Solicitation Posted
- Solicitation number
- 75N95024Q00198
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- Place of performance
- Mountain View, California 94043, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute on Drug Abuse (NIDA), on behalf of the National Center for Advanced Translational Sciences (NCATS), is seeking to procure six (6) dCas9-KRAB cell lines through a non-competitive request for quotation (RFQ). These cell lines will be used by the NCATS Functional Genomics Lab to conduct genome-wide CRISPR interference (CRISPRi) screens, which will repress target gene expression to identify promising gene targets and gain insights. The evaluation criteria include technical capability, price, and past performance. Responses are due by March 22, 2024, with anticipated performance from April 3 to June 26, 2024.
This acquisition is a non-competitive commercial item or service procurement conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures and FAR Part 12-Acquisition of Commercial Items. The NAICS code is 541711 (Research and Development in Biotechnology) and the PSC code is A913 (R&D-Biotechnology). The sole source of the cell lines is Cellecta, Inc. located in Mountain View, California. The estimated value of the contract is not specified, and the place of performance is Mountain View, CA.
Notice text
The solicitation number is 75N95024Q00198 and the solicitation is issued as a request for quotation (RFQ).
This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.
THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advanced Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to the following for the acquisition of six (6) dCas9-KRAB cell lines:
Cellecta, Inc.
320 Logue Avenue,
Mountain View, CA 94043
This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1).
This requirement is for the following services:
The National Institutes of Health has established an RNAi/CRIPSR Cas9 screening facility to provide intramural researchers with access to the equipment and expertise necessary to conduct genome-wide RNAi/ CRIPSR Cas9 screens in mammalian cells.
The NCATS Functional Genomics Lab requires six (6) dCas9 cell lines that will be used to repress the target gene expression when applied in a CRISPRi screen. See attached Statement of Work.
Files
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity